DISEASE CHARACTERISTICS:

• Histologically confirmed Hodgkin's lymphoma at time of relapse or disease progression, meeting all of the following criteria:

  • Stage I-IV disease

  • Meets 1 of the following criteria:

    • Mixed cellularity
    • Lymphocytic depletion (LD)
    • LD, diffuse fibrosis
    • LD, reticular
    • Lymphocyte predominance (LP)
    • LP, diffuse
    • LP, nodular
    • Nodular sclerosis (NS)
    • NS, cellular phase
    • NS, lymphocytic predominance
    • NS, mixed cellularity
    • NS, LD
    • Not otherwise specified
  • No morphologically unclassifiable disease

• Primary refractory disease OR disease in first relapse, except for the following:

  • Patients achieving a complete response after treatment on protocol COG-AHOD0431 who experience a biopsy-proven recurrence after doxorubicin hydrochloride, vincristine, prednisone, and cyclophosphamide without involved-field radiotherapy
  • Patients on the observation-only arm of protocol COG-AHOD0431

• Measurable disease, defined as 1 of the following:

  • Any nodal mass with the longest traverse diameter > 2 cm
  • Any measurable, focal mass lesion of a visceral organ (e.g., liver, spleen, or kidney)

• Patients with metastatic disease to bone marrow and granulocytopenia, anemia, and/or thrombocytopenia are allowed provided both of the following criteria are met:

  • Platelet count ≥ 20,000/mm³ (platelet transfusion allowed)
  • Hemoglobin ≥ 8 g/dL (packed red blood cell transfusion allowed)

PATIENT CHARACTERISTICS:

• Karnofsky performance status (PS) 60-100% (for patients > 16 years of age) OR Lanksy PS 60-100% (for patients ≤ 16 years of age)
• Life expectancy ≥ 2 months
• Absolute neutrophil count ≥ 1,000/mm³
• Platelet count ≥ 75,000/mm³ (transfusion independent) (for patients with no bone marrow involvement)
• Creatinine ≤ 1.5 times upper limit of normal (ULN)
• Creatinine clearance or radioisotope glomerular filtration rate ≥ 70 mL/min/1.73 m^2
• AST and ALT ≤ 2.5 times ULN
• Bilirubin ≤ 1.5 times ULN
• Shortening fraction ≥ 27% by echocardiogram OR LVEF ≥ 50% by gated radionuclide study
• Patients with a seizure disorder are eligible if on a nonenzyme-inducing anticonvulsant and seizures are well controlled
• No CNS toxicity > grade 2
• No serious intercurrent illnesses
• No known hypersensitivity to E.coli-derived proteins, filgrastim (G-CSF), or any component of the study drugs
• No peripheral neuropathy > grade 1
• No known hypersensitivity to bortezomib, boron, or mannitol
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception

PRIOR CONCURRENT THERAPY:

• See Disease Characteristics
• Recovered from prior therapy
• No prior bortezomib or other proteasome inhibitors
• At least 3 weeks since prior chemotherapy (4 weeks for nitrosoureas)
• More than 14 days since prior investigational drugs

• No concurrent enzyme inducing anticonvulsants that alter p450 metabolism, including phenytoin, carbamazepine, phenobarbital, or other anticonvulsants

  • Benzodiazepine or gabapentin allowed

• No other concurrent chemotherapy or immunomodulating agents (including steroids)

  • Concurrent corticosteroids allowed for treatment or prophylaxis of anaphylactic reactions
  • No dexamethasone or aprepitant as an antiemetic